Logo image
Immunotherapies for Immune-Mediated myopathies: A current perspective
Journal article   Peer reviewed

Immunotherapies for Immune-Mediated myopathies: A current perspective

M. Needham and F.L. Mastaglia
Neurotherapeutics, Vol.13(1), pp.132-146
2015
url
Link to Published Version *Subscription may be requiredView
url
Free to Read *No subscription requiredView

Abstract

Until recently, the treatment of immune-mediated inflammatory myopathies has largely been empirical with glucocorticoids, steroid-sparing immunosuppressive drugs, and intravenous immunoglobulin. However, a proportion of patients are only partially responsive to these therapies, and there has been a need to consider alternative treatment approaches. In particular, patients with inclusion body myositis are resistant to conventional immunotherapies or show only a transient response, and remain a major challenge. With increasing recognition of the different subtypes of immune-mediated inflammatory myopathies, and improved understanding of their pathogenesis, more targeted treatments are now being trialled. The overall approach to treatment, and novel therapies targeting B cells, T cells, and specific cytokines are discussed in this review.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.106 Rheumatology
1.106.1684 Dermatomyositis
Web Of Science research areas
Clinical Neurology
Neurosciences
Pharmacology & Pharmacy
ESI research areas
Neuroscience & Behavior
Logo image